Dehydrocholic acid/homatropine

A acemic monohydroxy fatty acids resulting from the non-enzymatic oxidation of linoleic acid.

(S)-GNE-140 is the less active enantiomer of GNE-140 which can inhibit Lactate dehydrogenase A ( LDHA ).Form:SolidIC50&amp: Target:LDHA.

(S)-GNE-140 is the less active enantiomer of GNE-140 which can inhibit Lactate dehydrogenase A ( LDHA ).Form:SolidIC50&amp: Target:LDHA.

(S)-GNE-140 is the less active enantiomer of GNE-140 which can inhibit Lactate dehydrogenase A ( LDHA ).Form:SolidIC50&amp: Target:LDHA.

(S)-GNE-140 is the less active enantiomer of GNE-140 which can inhibit Lactate dehydrogenase A ( LDHA ).Form:SolidIC50&amp: Target:LDHA.

(S)-GNE-140 is the less active enantiomer of GNE-140 which can inhibit Lactate dehydrogenase A ( LDHA ).Form:SolidIC50&amp: Target:LDHA.

(S)-GNE-140 is the less active enantiomer of GNE-140 which can inhibit Lactate dehydrogenase A ( LDHA ).IC50&amp: Target:LDHA.

Peptide Sequence: human 11&beta-HSD1 amino acids 78-92 (CLELGAASAHYLAGT) To be used in conjunction with Cayman&rsquos 11&beta-HSD1 polyclonal antibody (Catalog No. 10004303) to block protein-antibody complex formation during immunochemical

A cell-permeable, thiazolidinedione derivative that acts as a 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor (IC 50 = 25 nM). It is shown to increase PGE2 levels in IL-1&#946-stimulated A549 cells, dose-dependently, in the range of

An immediate precursor of cholesterol elevated in the neurodevelopmental syndrome Smith-Lemli-Opitz syndrome, where it is subject to free radical oxidation, giving rise to several oxysterols which contribute to pathogenesis converted by

[His⁵,Arg¹⁹]PTH-(1-34) (human).

[His⁵,Arg¹⁹]PTH-(1-34) (human).